Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
On Oct. 14, 2026, BICX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Biocorrx Inc. is a small-cap company with a market capitalization of $7M.
A per-ticker accuracy statistic for BICX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BICX included.
Follow BICX free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Specialty Outpatient Facilities, NEC peers listed below that report each metric.
| Metric | BICX | Rank |
|---|---|---|
| Market Cap | $7M | – |
| EPS | $-0.15 | – |
| Revenue/Share | $0.03 | – |
| Metric | BICX | Rank |
|---|---|---|
| ROA | -165.7% | – |
| ROIC | 70.5% | – |
| Gross Margin | 34.6% | – |
| Operating Margin | -623.1% | – |
| Net Margin | -401.9% | – |
| EBT Margin | -399.4% | – |
| Tax Rate | 0.0% | – |
| Metric | BICX | Rank |
|---|---|---|
| Current Ratio | 0.07x | – |
| Quick Ratio | 0.07x | – |
| Interest Coverage | -48.8x | – |
| Working Capital | -$8M | – |
| Metric | BICX | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | – |
| Metric | BICX | Rank |
|---|---|---|
| Asset Turnover | 0.41x | – |
| Receivables Turnover | 11.6x | – |
| Inventory Turnover | 3.3x | – |
| Days Sales Outstanding | 31 days | – |
| Days Inventory | 111 days | – |
| Payables Period | 11308 days | – |
| Cash Conversion Cycle | -11166 days | – |
| Metric | BICX | Rank |
|---|---|---|
| Total Revenue | $0.00M | – |
| Operating Income | -$4M | – |
| Net Income | -$3M | – |
| R&D Expense | $2M | – |
| SG&A Expense | $3M | – |
| Cost of Goods Sold | $140K | – |
| Metric | BICX | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
| Total Current Assets | $620K | 32.6% of assets |
| Cash & Short-term Investments | $20K | 1.1% of assets |
| Accounts Receivable | $70K | 3.7% of assets |
| Inventory | $40K | 2.1% of assets |
| Total Liabilities | $14M | 756.8% of assets |
| Short-term Debt | $4M |
Companies classified under the same SEC industry code as Biocorrx Inc. (Services-Specialty Outpatient Facilities, NEC): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeThis will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an ...
ANAHEIM, CA - March 11, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of innovative treatment support programs for substance abuse and related disorders, ...
BioCorRx BICX updated market data is now available on Standard & Poor Capital IQ Factual Stock Reports, S&P Capital IQ stated in a news release. S&P Capital IQ started its coverage on the stocks of ...
On Oct. 14, 2026, BICX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
A per-ticker accuracy statistic for BICX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Biocorrx Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
4 issuers in our coverage, BICX included, share the SEC industry code Services-Specialty Outpatient Facilities, NEC. The largest are: Concentra Group Holdings Parent, Inc. (CON), Acadia Healthcare Company, Inc. (ACHC), Elite Health Systems Inc. (EHSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.